Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
Open accessAbstract
Psychedelic drugs are increasingly being incorporated into therapeutic contexts for the purposes of promoting mental health. However, they can also induce adverse reactions in some individuals, and it is difficult to predict before treatment who is likely to experience positive or adverse acute effects. Although consideration of setting and dosage as well as excluding individuals with psychotic predispositions has thus far led to a high degree of safety, it is imperative that researchers develop a more nuanced understanding of how to predict individual reactions. To this end, the current systematic review coalesced the results of 14 studies that included baseline states or traits predictive of the acute effects of psychedelics. Individuals high in the traits of absorption, openness, and acceptance as well as a state of surrender were more likely to have positive and mystical-type experiences, whereas those low in openness and surrender or in preoccupied, apprehensive, or confused psychological states were more likely to experience acute adverse reactions. Participant sex was not a robust predictor of drug effects, but 5-HT2AR binding potential, executive network node diversity, and rACC volume may be potential baseline biomarkers related to acute reactions. Finally, increased age and experience with psychedelics were individual differences related to generally less intense effects, indicating that users may become slightly less sensitive to the effects of the drugs after repeated usage. Although future well-powered, placebo-controlled trials directly comparing the relative importance of these predictors is needed, this review synthesizes the field’s current understanding of how to predict acute reactions to psychedelic drugs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients who exhibit apprehension, preoccupation, or baseline attachment avoidance appear to be more likely to have challenging experiences following administration of a psychedelic drug.
“patients who exhibit apprehension, preoccupation, or baseline attachment avoidance appear to be more likely to have challenging experiences following administration of a psychedelic drug”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [281]
Previous research suggested a general trend toward reduced psychedelic drug effects with advancing age.
“To our knowledge, this is the first report of a relationship between age and psychedelic-induced ego dissolution, but previous research suggested a general trend toward reduced psychedelic drug effects (Aday et al., 2021) or fewer impairments of control and cognition with advancing age (Studerus et al., 2012).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Aday et al., 2021
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,759 · see citing works
The file drawer problem and tolerance for null results.
Rosenthal, R. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.3.638 · Cited by 9,068 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · see citing works
Self-citationHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · see citing works
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · see citing works
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · see citing works
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works
Biomarkers: Potential uses and limitations
Mayeux, R. P. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.182 · Cited by 925 · see citing works
Pilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · see citing works
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808 · see citing works
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · see citing works
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541 · see citing works
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520 · see citing works
Carbonaro, T. M., Bradstreet, M. P., Barrett, F., Maclean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 494 · see citing works
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · see citing works
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453 · see citing works
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417 · see citing works
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · see citing works
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · see citing works
Self-citationPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369 · see citing works
A High-Resolution<i>In Vivo</i>Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368 · see citing works
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339 · see citing works
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329 · see citing works
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · see citing works
Anderson, B. T., Danforth, A., Daroff, P. R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M. T., Dilley, P. J., Mitchell, J., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100538 · Cited by 284 · see citing works
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257 · see citing works
Self-citationGriffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214377 · Cited by 247 · see citing works
Self-citationREACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT
Leary, T., Litwin, G. H., & Metzner, R. (1963) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196312000-00007 · Cited by 245 · see citing works
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · see citing works
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · see citing works
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212 · see citing works
SANTOS, R. G. D., Landeira-Fernández, J., Strassman, R. J., Motta, V., & Cruz, A. P. D. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.04.012 · Cited by 205 · see citing works
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197 · see citing works
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 195 · see citing works
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188 · see citing works
Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019) · Scientific Reports · doi:10.1038/s41598-019-50612-3 · Cited by 176 · see citing works
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168 · see citing works
Brouwer, A., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 159 · see citing works
Kettner, H., Gandy, S., Haijen, E. C. H. M., & Carhart-Harris, R. L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245147 · Cited by 158 · see citing works
Comparison of the reactions induced by psilocybin and LSD-25 in man
Isbell, H. (1959) · Psychopharmacology · doi:10.1007/bf00408109 · Cited by 140 · see citing works
Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K., & Liechti, M. E. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv072 · Cited by 112 · see citing works
Spriggs, M. J., Kettner, H., & Carhart-Harris, R. L. (2021) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-020-01000-8 · Cited by 105 · see citing works
The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients
Richards, W. A., Rhead, J., Dileo, F., Yensen, R., & Kurland, A. (1977) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1977.10472020 · Cited by 97 · see citing works
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96 · see citing works
Ott, U., Reuter, M., Hennig, J., & Vaitl, D. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30197 · Cited by 95 · see citing works
Lyvers, M., & Meester, M. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.736842 · Cited by 91 · see citing works
Absorption and hallucinatory experience
Glicksohn, J., & Barrett, T. R. (2003) · Applied Cognitive Psychology · doi:10.1002/acp.913 · Cited by 83 · see citing works
Barsuglia, J. P., Davis, A. K., Palmer, R. L., Lancelotta, R., Windham-Herman, A.-M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02459 · Cited by 80 · see citing works
Self-citationStenbæk, D. S., Madsen, M. K., Ozenne, B., Kristiansen, S., Burmester, D., Erritzøe, D., Knudsen, G. M., & Fisher, P. M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959609 · Cited by 80 · see citing works
Replication and extension of a model predicting response to psilocybin
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. M., & Elliott, M. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05279-z · Cited by 77 · see citing works
Bonson, K. R., & Murphy, D. L. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00102-7 · Cited by 76 · see citing works
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Holze, F., Duthaler, U., Vizeli, P., Müller, F., Borgwardt, S., & Liechti, M. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13918 · Cited by 73 · see citing works
Prescribing for the elderly patient: why do we need to exercise caution?
Hughes (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00842.x · Cited by 72 · see citing works
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N., Thomas, C., & Hutson, P. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 67 · see citing works
Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65 · see citing works
Snell, W. E., Miller, R. S., Belk, S. S., Garcia-Falconi, R., & Hernández-Sánchez, J. E. (1989) · Sex Roles · doi:10.1007/bf00289098 · Cited by 63 · see citing works
States and Traits Related to the Quality and Consequences of Psychedelic Experiences
Russ, S., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. (2019) · Psychology of Consciousness · doi:10.1037/cns0000169 · Cited by 62 · see citing works
Self-reported negative outcomes of psilocybin users: A quantitative textual analysis
Bienemann, B., Ruschel, N. S., Campos, M. L. P., Negreiros, M., & Mograbi, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229067 · Cited by 61 · see citing works
2019: A year of expansion in psychedelic research, industry, and deregulation
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2020) · Drug Science Policy and Law · doi:10.1177/2050324520974484 · Cited by 60 · see citing works
Self-citationPsychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47 · see citing works
Self-citationA placebo-controlled investigation of synaesthesia-like experiences under LSD
Terhune, D. B., Luke, D. P., Kaelen, M., Bolstridge, M., Feilding, A., Nutt, D., Carhart-Harris, R. L., & Ward, J. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.04.005 · Cited by 45 · see citing works
The relationship between absorption, openness to experience, anhedonia, and susceptibility
Radtke, H. L., & Stam, H. J. (1991) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207149108409617 · Cited by 39 · see citing works
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T., Hoskins, M., & Sessa, B. (2020) · Human psychopharmacology · doi:10.1002/hup.2742 · Cited by 37 · see citing works
Lancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33 · see citing works
Self-citationKaasik, H., & Kreegipuu, K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1748773 · Cited by 31 · see citing works
Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
Kangaslampi, S., Hausen, A., & Rauteenmaa, T. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1767321 · Cited by 31 · see citing works
2018: A watershed year for psychedelic science
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2019) · Drug Science Policy and Law · doi:10.1177/2050324519872284 · Cited by 30 · see citing works
Self-citationLong-term psychological effects of LSD.
McWilliams, S. A., & Tuttle, R. J. (1973) · Psychological Bulletin · doi:10.1037/h0034411 · Cited by 27 · see citing works
Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.033 · Cited by 24 · see citing works
Self-citationRostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience
Lewis, C. R., Preller, K. H., Braden, B. B., Riecken, C., & Vollenweider, F. X. (2020) · Biomedicines · doi:10.3390/biomedicines8020034 · Cited by 22 · see citing works
Potentiation of LSD-induced stimulus control by fluoxetine in the rat
Fiorella, D. J., Helsley, S., Rabin, R. A., & Winter, J. C. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00490-0 · Cited by 18 · see citing works
Neural Mechanisms of Emotions and Affect
Aday, J. S., Rizer, W., & Carlson, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801851-4.00002-1 · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 327 · see citing works
Self-citationAday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237 · see citing works
Self-citationTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault‐Phillips, S., Nijdam, M. J., McFARLANE, A. C., & Vermetten, E. H. G. J. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 232 · see citing works
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178 · see citing works
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166 · see citing works
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150 · see citing works
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 119 · see citing works
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 121 · see citing works
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 100 · see citing works
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 93 · see citing works
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88 · see citing works
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 89 · see citing works
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D., & Carhart-Harris, R. (2024) · Psychological Medicine · doi:10.1017/s0033291723003653 · Cited by 89 · see citing works
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 85 · see citing works
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82 · see citing works
Self-citationKopra, E. I., Ferris, J., Winstock, A., Young, A., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084063 · Cited by 69 · see citing works
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 74 · see citing works
Sweeney, M. M., Nayak, S. M., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271926 · Cited by 64 · see citing works
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 68 · see citing works
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 63 · see citing works
Self-citationBarker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58 · see citing works
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58 · see citing works
Kopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 61 · see citing works
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58 · see citing works
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 66 · see citing works
Agin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54 · see citing works
“Finally, to address a substantial limitation present in previous literature (Aday et al., 2021; Muthukumaraswamy et al., 2021), expectancy, demand characteristics, and invalid responding were controlled for using several validity scales.”
MethodDevelopment and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
McAlpine, R. G., Blackburne, G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-53829-z · Cited by 51 · see citing works
Aday, J. S., Skiles, Z., Eaton, N., Fredenburg, L., Pleet, M. M., Mantia, J., Bradley, E., Fernandes‐Osterhold, G., & Woolley, J. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0004 · Cited by 50 · see citing works
Self-citationPsychological and physiological effects of extended DMT
Luan, L. X., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231196877 · Cited by 51 · see citing works
The costs and benefits of psychedelics on cognition and mood
Sayalı, C., & Barrett, F. S. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.031 · Cited by 43 · see citing works
Borkel, L. F., Rojas‐Hernández, J., Henríquez‐Hernández, L. A., Santana, Á., & Hernández, D. J. Q. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295997 · Cited by 47 · see citing works
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 43 · see citing works
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 40 · see citing works
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36 · see citing works
Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
Mallaroni, P., Mason, N. L., Reckweg, J. T., Paci, R., Ritscher, S., Toennes, S. W., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2958 · Cited by 39 · see citing works
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 37 · see citing works
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 37 · see citing works
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 37 · see citing works
Manifest your desires: Psychedelics and the self-help industry.
Plesa, P., & Petranker, R. (2022) · The International journal on drug policy · doi:10.1016/j.drugpo.2022.103704 · Cited by 28 · see citing works
Arnaud, K. O. S., & Sharpe, D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2039815 · Cited by 33 · see citing works
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 34 · see citing works
Breathwork-induced psychedelic experiences modulate neural dynamics
Lewis-Healey, E., Tagliazucchi, E., Canales‐Johnson, A., & Bekinschtein, T. A. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae347 · Cited by 33 · see citing works
Lake, S., & Lucas, P. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0002 · Cited by 34 · see citing works
Harnessing placebo: Lessons from psychedelic science
Pronovost-Morgan, C., Hartogsohn, I., & Ramaekers, J. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231182602 · Cited by 33 · see citing works
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 34 · see citing works
Zeifman, R. J., Kettner, H., Pagni, B. A., Mallard, A. J., Roberts, D. E., Erritzøe, D., Ross, S., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-40856-5 · Cited by 33 · see citing works
Engel, L. B., Thal, S. B., & Bright, S. J. (2022) · Contemporary Drug Problems · doi:10.1177/00914509221121420 · Cited by 30 · see citing works
On Minimizing Risk and Harm in the Use of Psychedelics
Evans, J., Aixalà, M., Anderson, B. T., Brennan, W., Bremler, R., Breeksema, J. J., Burback, L., Calder, A. E., Carhart-Harris, R. L., Cheung, K., et al. (2025) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20240128 · Cited by 29 · see citing works
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 28 · see citing works
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 30 · see citing works
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study
Wood, M. J., McAlpine, R. G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-79931-w · Cited by 29 · see citing works
Ko, K., Carter, B., Cleare, A. J., & Rucker, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s426193 · Cited by 28 · see citing works
Kaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 26 · see citing works
Simonsson, O., Carlbring, P., Carhart-Harris, R. L., Davis, A. K., Nutt, D., Griffiths, R. R., Erritzøe, D., & Goldberg, S. B. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115349 · Cited by 26 · see citing works
Self-citationMathai, D. S., Hull, T. D., Vando, L., & Malgaroli, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.131 · Cited by 24 · see citing works
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 26 · see citing works
Kruger, D. J., Aday, J. S., Fields, C. W., Kolbman, N., Glynos, N. G., Barron, J., Herberholz, M., & Boehnke, K. F. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0011 · Cited by 22 · see citing works
Self-citationDworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22 · see citing works
Tagliazucchi, E., Zamberlán, F., Cavanna, F., de la Fuente, L., Romero, C., Perl, Y. S., & Pallavicini, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720066 · Cited by 25 · see citing works
Callon, C., Williams, M., & Lafrance, A. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211043300 · Cited by 21 · see citing works
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21 · see citing works
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 20 · see citing works
Moreton, S. G., Burden-Hill, A., & Menzies, R. E. (2022) · Clinical Psychologist · doi:10.1080/13284207.2022.2086793 · Cited by 20 · see citing works
Bonnelle, V., Feilding, A., Rosas, F. E., Nutt, D. J., Carhart-Harris, R. L., & Timmermann, C. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241276788 · Cited by 20 · see citing works
Perna, J., Trop, J., Palitsky, R., Bosshardt, Z., Vantine, H., Dunlop, B. W., & Zarrabi, A. J. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06303-z · Cited by 19 · see citing works
Solaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 20 · see citing works
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20 · see citing works
“…this is the first report of a relationship between age and psychedelic-induced ego dissolution, but previous research suggested a general trend toward reduced psychedelic drug effects (Aday et al., 2021) or fewer impairments of control and cognition with advancing age (Studerus et al., 2012).”
ResultSjöström, D. K., Claesdotter‐Knutsson, E., & Kajonius, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-60890-1 · Cited by 18 · see citing works
Development of a digital intervention for psychedelic preparation (DIPP)
McAlpine, R. G., Sacchet, M. D., Simonsson, O., Khan, M. M., Krajnović, K., Morometescu, L., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-54642-4 · Cited by 17 · see citing works
Validation of the imperial psychedelic predictor scale
Angyus, M., Osborn, S., Haijen, E. C. H. M., Erritzøe, D., Peill, J. M., Lyons, T., Kettner, H., & Carhart-Harris, R. L. (2024) · Psychological Medicine · doi:10.1017/s0033291724002204 · Cited by 17 · see citing works
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
Cherniak, A. D., Brulin, J. G., Mikulincer, M., Östlind, S., Carhart-Harris, R. L., & Granqvist, P. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148061 · Cited by 19 · see citing works
Kamilar-Britt, P., Gordis, E. B., & Earleywine, M. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0020 · Cited by 17 · see citing works
Set and Setting for Psychedelic Harm Reduction
Hartogsohn, I. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_509 · Cited by 19 · see citing works
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 20 · see citing works
Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study
Aday, J. S., Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2312980 · Cited by 18 · see citing works
Self-citationAcevedo, E. C., Uhler, S., White, K. P., & Al-Shawaf, L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2314729 · Cited by 16 · see citing works
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach
Agin-Liebes, G., & Davis, A. K. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_282 · Cited by 17 · see citing works
Self-citationFemales in Psychedelic Research: A Perspective for Advancing Research and Practice
Cohen, Z. Z., & Blest‐Hopley, G. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00255 · Cited by 15 · see citing works
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15 · see citing works
Kargbo, R. B. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00546 · Cited by 15 · see citing works
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Chambers, R., Stoliker, D., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02206-4 · Cited by 13 · see citing works
Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13 · see citing works
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Strand, N. H., Whitney, M. A., Johnson, B. W., Dunn, T., Attanti, S., Maloney, J. A., Misra, L., Gomez, D., Viswanath, O., Emami, E., et al. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01353-0 · Cited by 14 · see citing works
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13 · see citing works
Reframing psychedelic regulation: Tools, not treatments
Wolff, M., Gukasyan, N., Roseman, L., & Liknaitzky, P. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251348272 · Cited by 12 · see citing works
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 13 · see citing works
McGriff, S. A., Hecker, J. C., Maitland, A. D., Partilla, J. S., Baumann, M. H., & Glatfelter, G. C. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06795-x · Cited by 13 · see citing works
The Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 12 · see citing works
Psychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)
Kopra, E. I., Penttinen, J., Rucker, J., & Copeland, C. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111177 · Cited by 12 · see citing works
Mathai, D. S., Roberts, D. E., Nayak, S. M., Sepeda, N. D., Lehrner, A. L., Johnson, M. W., Lowe, M. X., Jackson, H., & Garcia‐Romeu, A. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2461997 · Cited by 14 · see citing works
Focusing on the negative: cases of long-term negative psychological responses to psychedelicsPreprint
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · doi:10.31234/osf.io/yzmcj · Cited by 11 · see citing works
The Epidemiology of Psychedelic Use Among United States Military Veterans
Davis, A. K., Bates, M. J., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., Koffman, R. L., Hooyer, K., & Yehuda, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2401977 · Cited by 11 · see citing works
Self-citationHirschfeld, T., Smit‐Rigter, L. A., van der Gouwe, D., Reiche, S., Stöver, H., & Majić, T. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00385-5 · Cited by 10 · see citing works
Extended Difficulties Following the Use of Psychedelic Drugs: A Mixed Methods StudyPreprint
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., & McAlpine, R. G. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4487243 · Cited by 10 · see citing works
Considering distinct positive emotions in psychedelic science
Goldy, S. P., Hendricks, P. S., Keltner, D. J., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2394221 · Cited by 9 · see citing works
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Silva, S. R. B., Pantrigo, É. J., Medina, M., Arichelle, F., de Almeida, R. N., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.002 · Cited by 9 · see citing works
Examining the biological causes of eating disorders to inform treatment strategies
Foldi, C. J., & Griffiths, K. R. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00940-3 · Cited by 9 · see citing works
Oña, G., Révész, D., Kohek, M., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2022) · Psychoactives · doi:10.3390/psychoactives1010003 · Cited by 10 · see citing works
Psychological and physiological effects of extended DMTPreprint
Luan, L. X., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D. J., et al. (2023) · doi:10.31234/osf.io/vg4dp · Cited by 9 · see citing works
- Authors
- Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C.
- Affiliations
- Central Michigan University (US)
- Johns Hopkins University (US)
- Corresponding author
- Aday, Jacob S.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-05
- Volume
- 4
- Issue
- 2
- Pages
- 424-435
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033773
- OpenAlex
- W3134897339
- Cited by
- 224
- References
- 78
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 58 · 2023: 42 · 2022: 32 · 2021: 14
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the?Steven?and Alexandra Cohen Foundation
- Blake Mycoskie
- Craig?Nerenberg
- Matt Mullenweg
- Tim Ferriss
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- psychedelics, acute drug effects, adverse drug reactions, mystical experience, personality traits, absorption, openness to experience, acceptance, psychological state, surrender, executive network, biomarkers, individual differences, psychedelic experience
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review